🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

226 results for “Pfizer” Clear

  1. EVEROLIMUS, EVEROLIMUS, PF-07248144, FULVESTRANT, EVEROLIMUS, EXEMESTANE, FULVESTRANT, PF-07248144

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  2. Femara 2.5 mg film-coated tablets, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Anastrozole 1mg film-coated tablets, Docetaxel Pfizer 10 mg/mL concentrate for solution for infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Exemestane 25 mg Film-coated Tablets, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Cancer Prevention Pharma (Ireland) Limited

    low-grade serous carcinoma of the ovary or peritoneum

    phase 3 small molecule active

    1 trial

  3. Fordadistrogene Movaparvovec, ECULIZUMAB, Placebo for PF-06939926

    Pfizer Ireland Pharmaceuticals Unlimited Company

    DUCHENNE MUSCULAR DYSTROPHY (DMD)

    phase 3 small molecule active

    1 trial

  4. GEMCI-cell® 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Gemcitabine 1 g Powder for Solution for Infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Carbomedac® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusio

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated Unresectable or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  5. GEMCITABINE, Mrtx1719 matching placebo, PACLITAXEL ALBUMIN-BOUND, MRTX1719

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  6. GEMCITABINE, PEGFILGRASTIM, PACLITAXEL ALBUMIN-BOUND, BL-B01D1, CAPECITABINE, CARBOPLATIN, PACLITAXEL, CAPECITABINE

    Bristol-Myers Squibb / Pfizer EEIG

    Breast cancer, Triple-negative breast cancer

    phase 3 small molecule active

    1 trial

  7. Humira 40 mg solution for injection in pre-filled syringe, Abatacept

    Bristol-Myers Squibb / Pfizer EEIG

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  8. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, Ipilimumab, Sutent 12.5 mg hard capsules, Sutent 12.5 mg hard capsules

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or Metastatic Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  9. KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sigvotatug vedotin, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Pfizer Ireland Pharmaceuticals Unlimited Company

    non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  10. KarX-EC, KarX-EC, KarX-EC matching placebo, KarXT, KarXT, KarX-EC, KarX-EC, KarXT matching placebo, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  11. KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  12. KarX-EC, KarXT, KarX-EC matching placebo, KarX-EC, KarXT, KarXT, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb / Pfizer EEIG

    Mild to moderate Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  13. KarXT, KarX-EC matching Placebo, KarX-EC, KarXT matching Placebo, KarXT, KarX-EC, KarX-EC, KarX-EC, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  14. KarXT, KarX-EC, KarX-EC, KarXT, KarXT, KarX-EC matching Placebo, KarXT matching placebo, KarXT, KarX-EC, KarX-EC

    Bristol-Myers Squibb / Pfizer EEIG

    Agitation Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  15. KarXT, KarXT Matching Placebo, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Schizophrenia

    phase 3 small molecule active

    1 trial

  16. KarXT, KarXT, KarXT, KarXT

    Bristol-Myers Squibb / Pfizer EEIG

    Mania or Mania with Mixed Features in Bipolar-I Disorder

    phase 3 small molecule active

    1 trial

  17. KarXT, KarXT, KarXT, KarXT Matching Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  18. KarXT, KarXT, KarXT, KarXT, KarXT Matching Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  19. KarXT, KarXT, KarXT, KarXT, KarXT, Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    Psychosis Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  20. KarXT, KarXT, KarXT, Karxt Matching Placebo

    Bristol-Myers Squibb / Pfizer EEIG

    BP-I mania or mania with mixed features

    phase 3 small molecule active

    1 trial

  21. LETROZOLE, IBRANCE 75 mg hard capsules, RIBOCICLIB, ABEMACICLIB, IBRANCE 100 mg hard capsules, ABEMACICLIB, IBRANCE 125 mg hard capsules, ABEMACICLIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Advanced/Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  22. LORLATINIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Advanced ALK positive non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  23. LORLATINIB, AXITINIB, AVELUMAB, AXITINIB, TALAZOPARIB, TALAZOPARIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Cancer

    phase 3 small molecule active

    1 trial

  24. LPA1 antagonist, LPA1 antagonist, Placebo for BMS-986278

    Bristol-Myers Squibb / Pfizer EEIG

    Idiopathic pulmonary fibrosis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources